SAB BIOTHERAPEUTICS, INC. Proceeds from Issuance of Warrants
SAB BIOTHERAPEUTICS, INC. (SABS) reported Proceeds from Issuance of Warrants of $6.78 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-22.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2021-11-22
- 2021-09-30: Proceeds from Issuance of Warrants 9 month $6.78M.
| Period end | Proceeds from Issuance of Warrants 9 month |
|---|---|
| 2021-09-30 | $6.78M 10-Q · filed 2021-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |